| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8440568 | European Journal of Cancer | 2018 | 8 Pages |
Abstract
Veliparib was well tolerated, but no confirmed response was observed although four (25%) patients remained on study with SD for â¥Â 4 months. Additional strategies in this population are needed, and ongoing trials are evaluating PARPis combined with chemotherapy (NCT01585805) and as a maintenance strategy (NCT02184195).
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Maeve A. Lowery, David P. Kelsen, Marinela Capanu, Sloane C. Smith, Jonathan W. Lee, Zsofia K. Stadler, Malcolm J. Moore, Hedy L. Kindler, Talia Golan, Amiel Segal, Hannah Maynard, Ellen Hollywood, MaryEllen Moynahan, Erin E. Salo-Mullen,